Pharmaceutical Technology - October 2022

Pharmaceutical Technology - October 2022

Issue link: https://www.e-digitaleditions.com/i/1481708

Contents of this Issue

Navigation

Page 30 of 66

30 Pharmaceutical Technology ® Trends in Formulation 2022 eBook PharmTech.com MR.ILKIN - STOCK.ADOBE.COM T here is a growing demand for biologics spurred by clinical success, favorable safe- ty data, and the ability of biologics to target the underlying cause of disease. Progress in proteins, peptides, nucleic acids, vaccines, and mono- clonal antibodies (mAbs) has allowed biologics to ad- vance quickly, especially in recent years. According to an article in Molecules, 25% of new chemical en- tities approved by FDA between 2015 and 2019 were biologics (1). Perhaps the most striking recent exam- ple of the demand for biologics is the rapid scale-up and application of messenger RNA (mRNA) vaccines to treat COVID-19. Though progress has been swift, challenges have created barriers to global adoption due to complications related to formulation, thermo- stability, and drug delivery. Biologics originate from living organisms, have large molecular weights, and generally cannot be chemically synthesized. This means they are vulner- able to the environment and require extreme care to formulate, manufacture, and store (2). As biologics are large molecules with primary, secondary, tertiary, and quaternar y structures, they are also sensitive and expensive to produce (3). While biologics are con- ventionally delivered intravenously in liquid form, liquid formulations exhibit chemical and physical stability problems. Conversely, biologics formulated as a dry powder are more stable and are less prone to degradation, but drug manufacturers must con- sider shelf stability as well as which excipients and formulation conditions will enable a longer shelf life. Additionally, the chemical and physical properties of Improved Formulations to Enable Stable Delivery of Biologics Robert O. Williams III, PhD is the technology inventor/ special advisor for TFF Pharmaceuticals. How dry powder techniques can overcome limitations in biologics development and delivery to broaden routes of administration and global accessibility.

Articles in this issue

Links on this page

Archives of this issue

view archives of Pharmaceutical Technology - October 2022 - Pharmaceutical Technology - October 2022